2019 Future of Left Ventricular Dysfunction R&D Pipeline Drugs and Companies- Analysis of Global Left Ventricular Dysfunction Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Left Ventricular Dysfunction treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Left Ventricular Dysfunction pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Left Ventricular Dysfunction pipeline companies from advancing their products into Phase 3 or Phase 4.
Left Ventricular Dysfunction Report Description
The H1 2019 pipeline review report on Left Ventricular Dysfunction pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Left Ventricular Dysfunction pipeline compounds.
The Left Ventricular Dysfunction pipeline guide presents information on all active drugs currently being developed for Left Ventricular Dysfunction. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Left Ventricular Dysfunction pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Left Ventricular Dysfunction drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Left Ventricular Dysfunction product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Left Ventricular Dysfunction pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Left Ventricular Dysfunction pipeline report includes
REASONS TO BUY
Left Ventricular Dysfunction Report Description
The H1 2019 pipeline review report on Left Ventricular Dysfunction pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Left Ventricular Dysfunction pipeline compounds.
The Left Ventricular Dysfunction pipeline guide presents information on all active drugs currently being developed for Left Ventricular Dysfunction. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Left Ventricular Dysfunction pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Left Ventricular Dysfunction drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Left Ventricular Dysfunction product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Left Ventricular Dysfunction pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Left Ventricular Dysfunction pipeline report includes
- An overview of Left Ventricular Dysfunction disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of pipeline compounds
- Company wise list of pipeline compounds
- Mechanism of Action wise pipeline compounds
- For each pipeline product, the following details are provided-
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials
REASONS TO BUY
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Left Ventricular Dysfunction pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Left Ventricular Dysfunction pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into the market through in-depth strategic analysis review
- Know the list of companies participating in global Left Ventricular Dysfunction pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL LEFT VENTRICULAR DYSFUNCTION PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Left Ventricular Dysfunction Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Left Ventricular Dysfunction pipeline, H1- 2019
3.5 Mechanism of Action wise Left Ventricular Dysfunction Pipeline Candidates
4. ARMARON BIO PTY LTD. LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
4.1 Armaron Bio Pty Ltd. Business Profile
4.2 Armaron Bio Pty Ltd. Left Ventricular Dysfunction Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. BAYER AG LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
5.1 Bayer AG Business Profile
5.2 Bayer AG Left Ventricular Dysfunction Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. INNOPHARMAX INC. LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
6.1 Innopharmax Inc. Business Profile
6.2 Innopharmax Inc. Left Ventricular Dysfunction Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. MESOBLAST LTD LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
7.1 Mesoblast Ltd Business Profile
7.2 Mesoblast Ltd Left Ventricular Dysfunction Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. NOVARTIS INTERNATIONAL AG LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
8.1 Novartis International AG Business Profile
8.2 Novartis International AG Left Ventricular Dysfunction Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. QUANTUM GENOMICS CORP. LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
9.1 Quantum Genomics Corp. Business Profile
9.2 Quantum Genomics Corp. Left Ventricular Dysfunction Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. REDHILL BIOPHARMA LTD. LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
10.1 Redhill Biopharma Ltd. Business Profile
10.2 Redhill Biopharma Ltd. Left Ventricular Dysfunction Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. TIGENIX NV LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
11.1 TiGenix NV Business Profile
11.2 TiGenix NV Left Ventricular Dysfunction Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. LATEST LEFT VENTRICULAR DYSFUNCTION DRUG PIPELINE DEVELOPMENTS, 2019
13. APPENDIX
13.1 About Us
13.2 Sources and Methodology
13.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL LEFT VENTRICULAR DYSFUNCTION PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Left Ventricular Dysfunction Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Left Ventricular Dysfunction pipeline, H1- 2019
3.5 Mechanism of Action wise Left Ventricular Dysfunction Pipeline Candidates
4. ARMARON BIO PTY LTD. LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
4.1 Armaron Bio Pty Ltd. Business Profile
4.2 Armaron Bio Pty Ltd. Left Ventricular Dysfunction Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. BAYER AG LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
5.1 Bayer AG Business Profile
5.2 Bayer AG Left Ventricular Dysfunction Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. INNOPHARMAX INC. LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
6.1 Innopharmax Inc. Business Profile
6.2 Innopharmax Inc. Left Ventricular Dysfunction Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. MESOBLAST LTD LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
7.1 Mesoblast Ltd Business Profile
7.2 Mesoblast Ltd Left Ventricular Dysfunction Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. NOVARTIS INTERNATIONAL AG LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
8.1 Novartis International AG Business Profile
8.2 Novartis International AG Left Ventricular Dysfunction Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. QUANTUM GENOMICS CORP. LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
9.1 Quantum Genomics Corp. Business Profile
9.2 Quantum Genomics Corp. Left Ventricular Dysfunction Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. REDHILL BIOPHARMA LTD. LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
10.1 Redhill Biopharma Ltd. Business Profile
10.2 Redhill Biopharma Ltd. Left Ventricular Dysfunction Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. TIGENIX NV LEFT VENTRICULAR DYSFUNCTION PIPELINE DETAILS
11.1 TiGenix NV Business Profile
11.2 TiGenix NV Left Ventricular Dysfunction Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. LATEST LEFT VENTRICULAR DYSFUNCTION DRUG PIPELINE DEVELOPMENTS, 2019
13. APPENDIX
13.1 About Us
13.2 Sources and Methodology
13.3 Contact Information
